1. Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT‐2 follow‐up and post‐hoc analyses on progression‐free survival and tumour growth. (5th July 2017) Authors: Dimopoulos, Meletios A.; Lonial, Sagar; White, Darrell; Moreau, Philippe; Palumbo, Antonio; San‐Miguel, Jesus; Shpilberg, Ofer; Anderson, Kenneth; Grosicki, Sebastian; Spicka, Ivan; Walter‐Croneck, Adam; Magen, Hila; Mateos, Maria‐Victoria; Belch, Andrew; Reece, Donna; Beksac, Meral; Bleickardt, ... Journal: British journal of haematology Issue: Volume 178:Number 6(2017) Page Start: 896 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗